CJC-1295 and Ipamorelin: The Growth Hormone Secretagogue Stack Every Research Lab Knows

If you ask ten researchers which two growth hormone secretagogues belong together in a single research protocol, most of them will say CJC-1295 and Ipamorelin without pausing. This stack has been the default GH secretagogue combination for over a decade because it is mechanistically coherent, well documented, and remarkably clean in its effect profile compared to older GH-releasing peptides like GHRP-2 and GHRP-6.

This guide explains the stack the way a research lab actually thinks about it. Not two peptides described side by side, but one coordinated protocol with a shared mechanism story and a reason for pairing them that older articles skip.

The short version

The stack works because the two peptides hit the pituitary gland through two different receptors that each do part of the job on their own. CJC-1295 is a GHRH analog, meaning it mimics growth hormone releasing hormone and tells the pituitary to release GH through the GHRH receptor. Ipamorelin is a ghrelin receptor agonist, meaning it triggers a separate ghrelin-mediated pulse that enhances and amplifies the GHRH signal. Running both together produces a larger, more physiologic GH pulse than either peptide alone.

That is why they are stacked. Not because more is better, but because the two receptor pathways are designed to work together.

Browse the CJC-1295 + Ipamorelin blend from LyzeLabs.

The mechanism in two signals

Signal 1: GHRH (the primary pulse)

Growth hormone releasing hormone (GHRH) is secreted by the hypothalamus and binds the GHRH receptor on somatotroph cells in the anterior pituitary. Binding triggers GH release through a cyclic AMP-dependent pathway.

CJC-1295 is a synthetic GHRH analog modified for improved stability and a longer half-life compared to native GHRH. Modifications at position 2 resist enzymatic breakdown, which is the main failure point of unmodified GHRH. The molecule comes in two forms: CJC-1295 without DAC (Drug Affinity Complex), which has an extended but still relatively short half-life, and CJC-1295 with DAC, which has an extended half-life of several days due to covalent binding to serum albumin.

Which form you choose depends on the research question, and that choice is the most common point of confusion for researchers new to the stack.

Signal 2: Ghrelin receptor (the amplifier)

Ghrelin is a hormone secreted by the stomach that, in addition to its appetite-related effects, binds the growth hormone secretagogue receptor (GHSR) on the same somatotroph cells in the anterior pituitary. Binding triggers GH release through a different pathway (primarily IP3/calcium signaling) than the GHRH pathway.

Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor selectively. The selectivity is the key feature. Older GH secretagogues like GHRP-2 and GHRP-6 also bind this receptor, but they also trigger cortisol and prolactin release as off-target effects, which confound metabolic research. Ipamorelin is selective enough to produce the GH pulse without the cortisol and prolactin noise.

Why both signals together are greater than the sum

When both the GHRH receptor and the ghrelin receptor are activated at the same time on the same somatotroph cells, the GH release pulse is larger than the additive expectation. The two pathways converge on GH secretion but they do so through different intracellular signaling cascades, and the combined activation produces synergistic release. This is the mechanistic rationale for the stack.

In research models, the combined stack produces a cleaner, larger, more pulsatile GH release than either peptide alone at equivalent dose ranges, and it does so without the side effect profile of older combinations.

CJC-1295 with DAC vs without DAC

This is the single most common point of confusion. Here is the short version.

CJC-1295 without DAC (short-acting)

The peptide retains its GHRH analog stability modifications but lacks the albumin-binding group. Half-life is in the minutes to hours range. This produces a sharp pulse of GH release that mirrors natural pulsatile GH secretion. Research protocols that study pulsatile dynamics or short-window GH effects typically use the no-DAC form.

CJC-1295 with DAC (long-acting)

The peptide includes the DAC modification, which covalently binds to serum albumin and extends the plasma half-life to several days. This produces a sustained elevation in baseline GH levels rather than a sharp pulse. Research protocols that study cumulative or long-duration GH effects typically use the DAC form.

The stack with Ipamorelin

Ipamorelin pairs with both forms, but the practical implications differ. With no-DAC CJC-1295, the stack produces a short coordinated pulse appropriate for protocols studying natural GH release patterns. With DAC, the stack produces a sustained GHRH signal with pulsatile ghrelin amplification, appropriate for protocols studying longer-duration outcomes.

LyzeLabs stocks CJC-1295 without DAC, CJC-1295 with DAC, Ipamorelin, and the CJC-1295 + Ipamorelin blend so that protocols can select the right form for the research question.

Why this stack beat GHRP-2 and GHRP-6

Older GH secretagogue stacks often paired CJC-1295 with GHRP-2 or GHRP-6 rather than Ipamorelin. Those combinations still exist in the LyzeLabs catalog because they remain useful for specific research questions, but the CJC + Ipamorelin combination displaced them as the default for three reasons.

• Cortisol and prolactin cleanliness. GHRP-2 and GHRP-6 trigger cortisol and prolactin release as side effects of their ghrelin receptor binding. Ipamorelin is selective enough to minimize this, producing a cleaner GH pulse.
• Appetite effects. GHRP-6 in particular produces strong appetite stimulation in research models, which is a confound in metabolic studies. Ipamorelin does not.
• Dose-response reliability. Ipamorelin shows more consistent dose-response behavior across a broader range in research models, which makes protocol design easier.

For research questions where cortisol and prolactin pathways are the study target, GHRP-2 or GHRP-6 may be the correct choice. For everything else, the CJC + Ipamorelin stack is cleaner.

Research applications

Pulsatile GH dynamics

Pairing no-DAC CJC-1295 with Ipamorelin produces a sharp, physiologic GH pulse that is used in research models of natural GH release patterns, sleep-associated GH secretion, and pulse-dependent downstream effects.

Sustained GH signaling research

Pairing DAC CJC-1295 with Ipamorelin produces elevated baseline GH with pulse amplification, used in research on longer-duration growth hormone signaling outcomes, hepatic IGF-1 responses, and sustained anabolic research models.

Age-related GH decline research

The natural decline in GH pulse amplitude with age is a well-studied phenomenon. CJC + Ipamorelin protocols are used to probe whether restoring pulsatile GH dynamics through dual-receptor secretagogue activation modifies outcome measures in aging models.

Tissue-specific GH effects

Because the stack produces endogenous GH release rather than supplying exogenous GH directly, research can probe the effects of pulsatile versus sustained GH on specific tissue compartments (muscle, bone, connective tissue) without confounds from the non-physiological kinetics of exogenous HGH dosing.

Comparison studies

The stack is frequently used as a reference arm in research comparing different GH-axis modulation strategies, including direct exogenous GH, pure GHRH analogs, pure ghrelin receptor agonists, and combinations.

Practical research considerations

Reconstitution

Both compounds are lyophilized powders and the blend format uses a single reconstitution protocol. Bacteriostatic water, swirl gently, no shaking. The CJC-1295 reconstitution calculator and the Ipamorelin reconstitution calculator handle the math for single-compound work.

Dose framing

Research protocols in the literature use microgram-range doses for both peptides, with ratios typically in the 1:1 range by mass for the blend format. Specific dosing depends on the research question and the form of CJC-1295 selected. Match doses to the precedent paper your protocol is replicating or extending.

Timing

Because the stack produces a pulse of GH release, timing matters for research design. Protocols often administer the stack at times corresponding to natural GH pulse windows (late evening or early morning) to align with physiologic circadian rhythms in the model system.

Sourcing

CJC-1295 in particular has a wide quality spread in the research peptide market because there are multiple synthesis routes and multiple molecular variants sold under similar names. Insist on per-batch HPLC purity, mass spec confirmation, and a clear label indicating whether the vial contains the DAC or no-DAC form. LyzeLabs publishes Janoshik COAs for each compound and the blend format separately. Run the COA verification routine before sourcing.

Frequently asked questions

Is CJC-1295 the same as Ipamorelin

No. They are structurally unrelated peptides that act on different receptors. CJC-1295 is a GHRH analog acting on the GHRH receptor. Ipamorelin is a ghrelin receptor agonist acting on the growth hormone secretagogue receptor (GHSR). They are stacked together because the two receptor pathways work synergistically, not because they are the same compound.

Why is Ipamorelin preferred over GHRP-2 and GHRP-6

Ipamorelin is the most receptor-selective of the three, producing GH release without meaningful cortisol or prolactin elevation and without the appetite stimulation associated with GHRP-6. For most research questions outside cortisol or appetite pathway work, Ipamorelin is the cleaner tool.

Which form of CJC-1295 should I use for my study

If your study is about pulsatile GH dynamics, short-window outcomes, or replicating a pulse-based protocol, use CJC-1295 without DAC. If your study is about sustained GH signaling, longer-duration outcomes, or a protocol using weekly-range dosing, use CJC-1295 with DAC. If your study is matching a precedent paper, match the form that paper used.

Is the blend format the same as doing two separate injections

Functionally, yes, in terms of receptor activation. Practically, the blend format reduces reconstitution error, simplifies dose consistency, and is typically more economical for multi-subject protocols. Separate vials give more flexibility for researchers who want to titrate the two compounds independently.

Can I stack CJC-1295 and Ipamorelin with other growth factors

Research stacks exist pairing the GH secretagogue combination with compounds like IGF-1 LR3, MGF, or Sermorelin in various configurations. Each additional compound adds complexity and potential confounds, so stack decisions should be driven by the research question, not by "more is better" logic. The growth factors category page has the full catalog.

How do I know which molecular weight to expect on a COA

CJC-1295 without DAC has a molecular weight of approximately 3367.9 Da. CJC-1295 with DAC is approximately 3647.2 Da. Ipamorelin is approximately 711.9 Da. A real mass spectrum on the COA should show a peak within tolerance of the expected value for the form you ordered.

The takeaway

CJC-1295 and Ipamorelin are stacked together for a mechanistic reason, not because combining peptides sounds more impressive than using one. The two signals converge on growth hormone release through different receptor pathways, and the combined activation produces a larger and cleaner GH pulse than either peptide alone. That is the entire reason this stack is the default in research peptide protocols.

If your research question calls for pulsatile GH dynamics, use CJC-1295 without DAC with Ipamorelin. If it calls for sustained GH signaling, use CJC-1295 with DAC with Ipamorelin. Or simplify the logistics with the premixed blend. Every batch tested, every report published, every vial matched to its COA.

This article is for research and educational purposes. All products sold by LyzeLabs are strictly for laboratory research and not intended for human consumption or therapeutic use.